EN DE
Watch AcouSort AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

AcouSort AB (ACOU) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of AcouSort AB stock SEK 0.46, price SEK 3.09, that is 85.1% below the price, quality 42 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0009189608

AA AcouSort AB logo Thin data Nov 4, 2026

AcouSort AB

ACOU · ST
Very expensive, weak quality

Our calculation puts a fair price 85% below what the stock costs today.

Quality 42/100
Expensive Growth (revenue 5y +6.8 %/yr in SEK)
Revenue last quarter 26% below a year ago.
Fair value kr 0.4590 · Strongly overvalued
Loss-making · -120.5% net margin (TTM)
Negative free cash flow
Trails peers (0/9)
Narrow moat 10/100 · thin data
Thin data
⚠ Dilution
Watch AcouSort AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 31.61 kr 2.13 Fair Value kr 0.4590 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range kr 2.13 – kr 31.61 · fair‑value band kr 0.3060 – kr 0.5780 · the kr 3.09 price screens above the kr 0.4590 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow AcouSort in your weekly email

Every Wednesday you see whether AcouSort is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets.

Show moreShow less

It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, a module that enables in-line analysis of blood plasma from whole blood samples; Acoustic Separation Module, a microfluidic solution that provides continuous separation, washing or up-concentration of cells; Acoustic Trapping Module, a microfluidic cell sorters or quality control systems for bioreactors and cell therapy production; AQC Module, an in-line optical analysis of particle suspensions for quality control or monitoring applications; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples.

The company has a collaboration agreement with Moeller Medical to exhibit a prototype system for analyzing separation of cells from body fluids. AcouSort AB (publ) was incorporated in 2010 and is based in Lund, Sweden.

Stock analysis

AcouSort AB (ACOU) currently trades at kr 3.09, while our model-based Fair Value estimate is kr 0.4590, 85% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: kr 0.3060 (bear) to kr 0.5780 (bull), the price of kr 3.09 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

AcouSort AB reported revenue of 6.9M SEK in FY2025 versus 3.0M SEK in FY2021, a compound +22.9%/yr. Reported net income was −12.2M SEK in FY2025.

Key figures

Market cap 65.4M SEK (≈ $6.6M) Micro · P/S ratio 7.32 · EPS (TTM) kr −0.5200 · Net margin −120% · Return on equity −72.3% · Return on assets (EBIT) −65.9% (5-year average) · Operating margin −169% · Revenue (TTM) 9.3M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 38% below its 52-week high and 45% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −85%, ACOU screens richer than that median.

Fair Value models

Bear kr 0.3060 Fair Value kr 0.4590 Bull kr 0.5780
Price kr 3.09 · Downside -85.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) kr 0.3600 kr 0.5400 kr 0.6800 52
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.3600 kr 0.5400 kr 0.6800 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 70
Are margins and returns getting better?
Cashflow 20
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 29
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 40
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 21/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+44.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.8%
Start year 2020 (pandemic). Over 10 years: +15.8% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−158.6% (2020) → −211.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ACOU screens overvalued: fair value 85% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare AcouSort AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 0/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 42 · Below median
Fair Value upside −85.1% · Bottom 25%
Profitability
Return on assets −67.9% · Bottom 25%
Net margin (12 months) −120.5% · Bottom 25%
Operating margin (12 months) −168.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −25.6% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.01× · Priciest 25%
P/S (12 months) 7.02× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs ACOU
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs ACOU
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs ACOU
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs ACOU
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs ACOU
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs ACOU
argenx SE ARGX $927.21 $908.40 −2% vs ACOU
CSL Limited CSL A$200.77 A$183.04 −9% vs ACOU
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs ACOU
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs ACOU

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

AcouSort AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "AcouSort AB Fair Value". https://www.fairvalue-calculator.com/stock/ACOU

Frequently asked questions

Is AcouSort AB (ACOU) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of kr 0.4590 versus a price of kr 3.09, about 85% lower (overvalued).
What is the fair value of ACOU?
Our model-based fair value for AcouSort AB is kr 0.4590 (as of Nov 4, 2026), built from audited fundamentals. The current price: kr 3.09.
What is the quality score of ACOU?
AcouSort AB has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AcouSort AB (ACOU)?
Our model-based price target is the fair value of kr 0.4590 (as of Nov 4, 2026) from 1 valuation models. Cautious scenario kr 0.3060, optimistic scenario kr 0.5780. It is a calculation from audited fundamentals, not an analyst target.
What is the AcouSort AB stock forecast for 2026?
Our models put fair value at kr 0.4590, about 85% lower versus a price of kr 3.09 (overvalued). Cautious scenario kr 0.3060, optimistic scenario kr 0.5780. The calculation is refreshed regularly with new filings.
What is the revenue of AcouSort AB (ACOU)?
AcouSort AB reported trailing-twelve-month revenue of about 9.3M SEK (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of AcouSort AB (ACOU)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AcouSort AB it is kr 0.4590 per share (as of Nov 4, 2026), against a price of kr 3.09. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is AcouSort AB stock overvalued or undervalued in 2026?
As of Nov 4, 2026, ACOU trades above its calculated fair value: price kr 3.09, fair value kr 0.4590, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ACOU?
No. The price is what the market pays today (kr 3.09); the fair value is what the company's own numbers justify (kr 0.4590). For AcouSort AB the two are kr 2.63 per share apart. That gap is exactly why we show both numbers side by side.
How much is AcouSort AB worth?
The market values AcouSort AB at about 65.4M SEK (market capitalisation, as of Nov 4, 2026). Per share that is kr 3.09; our models calculate a fair value of kr 0.4590 per share.
What do the bullish and bearish scenarios say about ACOU?
Our models span a range for AcouSort AB: cautious scenario kr 0.3060, base kr 0.4590, optimistic kr 0.5780 per share (as of Nov 4, 2026, price kr 3.09). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of AcouSort AB (ACOU)?
Balance-sheet figures for AcouSort AB (as of Nov 4, 2026): return on equity −72.3%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is ACOU from its 52-week high?
AcouSort AB trades at kr 3.09, about 38% below its 52-week high of kr 4.99 and 45% above the low of kr 2.13 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.4590 is for.
Which stocks are comparable to AcouSort AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AcouSort AB stock attractive at the current price?
The data as of Nov 4, 2026: price kr 3.09, calculated fair value kr 0.4590 (−85%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ACOU calculated?
We run AcouSort AB through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of kr 0.4590 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. AcouSort AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AcouSort AB (ACOU)?
The closing price on Nov 6, 2026 was kr 3.09. Our model-based fair value is kr 0.4590, about 85% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AcouSort AB right now?
The price sits above even our optimistic bull case (kr 0.5780). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.3060 to kr 0.5780) leaves room in how you read the outcome.

Key figures of AcouSort AB

How large is the market capitalisation of AcouSort AB (ACOU)?
The market capitalisation of AcouSort AB is 65.4M SEK (≈ $6.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AcouSort AB (ACOU)?
The price-to-sales ratio of AcouSort AB is 7.32 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AcouSort AB (ACOU)?
Earnings per share at AcouSort AB are kr −0.5200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of AcouSort AB (ACOU)?
The net margin of AcouSort AB is −120% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of AcouSort AB (ACOU)?
The return on equity (ROE) of AcouSort AB is −72.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AcouSort AB (ACOU)?
On an EBIT basis the return on assets of AcouSort AB is −65.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AcouSort AB (ACOU)?
The operating margin of AcouSort AB is −169% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AcouSort AB (ACOU)?
Revenue at AcouSort AB is growing −25.6% versus a year earlier (3y avg +11.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does AcouSort AB (ACOU) generate?
The free cash flow of AcouSort AB is −17.3M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does AcouSort AB (ACOU) hold?
AcouSort AB holds more cash than debt, 6.3M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch AcouSort AB in the live analysis

One click puts AcouSort AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.